FIA
ORMP icon

FNY Investment Advisers’s Oramed Pharmaceuticals ORMP Stock Holding History

FNY Investment Advisers’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,195
Closed -$48K – 748
2021
Q3 		$48K Buy
+2,195
New +$37.4K 0.02% 358

Other funds holding ORMP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

FNY Investment Advisers's ORMP Position: Q4 2021 in Review

FNY Investment Advisers sold out of Oramed Pharmaceuticals (ORMP) in Q4 2021, closing a stake of 2,195 shares — an estimated $48K sold.

FNY Investment Advisers first reported a position in ORMP in Q3 2021 and held it in 1 quarter. The position peaked at $48K in Q3 2021. 116 funds tracked by Wall St. Rank hold ORMP as of Q4 2021.

  • FNY Investment Advisers reported no remaining Oramed Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • FNY Investment Advisers sold 2,195 Oramed Pharmaceuticals shares in Q4 2021, an estimated $48K.
  • FNY Investment Advisers first reported a position in Oramed Pharmaceuticals in Q3 2021 and held it in 1 quarter.
  • FNY Investment Advisers's Oramed Pharmaceuticals position peaked at $48K in Q3 2021.
  • 116 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q4 2021.

Based on FNY Investment Advisers's 13F filing for Q4 2021, filed 10 Jan 2022.